Complementing our in-house research & development efforts, our partnering activities focus on our strategic therapeutic areas. In our constant quest for "Value through Innovation", we are engaged in successful ongoing partnerships and are actively seeking new collaborations with external partners ranging from academic institutions to start-up companies or biotechnological enterprises. Strong alliance management functions at Boehringer Ingelheim ensure high-level commitment to successful execution of partnerships.
|
Antibody technologies |
Antitope Ltd. Medarex, Inc. MorphoSys AG Xencor, Inc. |
|
Biomarker |
Caprion Proteomics, Inc. Rules-Based Medicine, Inc. |
|
Devices |
Vectura Group plc |
|
Disease related drug discovery |
Axxam SpA Evotec AG |
|
Fragment based screening |
Graffinity Pharmaceuticals GmbH |
|
High throughput screening |
Astex Therapeutics Ltd. Evotec AG |
|
Integrated electronic data handling |
Biomax Informatics AG Genomatix Software GmbH |
|
Medicinal chemistry |
Astex Therapeutics Ltd. Evotec AG Dalton Pharma Services |
|
Protein formulation development |
XstalBio Ltd. |
|
Protein crystallography |
Proteros biostructures GmbH |
|
Protein scaffold technologies |
Ablynx nv NascaCell Technologies AG |
|
RNAi-related target discovery |
Cenix BioScience GmbH |
|
Second generation biologics |
Syntonix Pharmaceuticals, Inc. |
|
Target validation and compound profiling |
Asterand plc Kinaxo Biotechnologies GmbH |
|
Therapeutic proteins |
AbGenomics, Corp. Evec, Inc. |